

VIRTUAL GLOBAL SUMMIT ON PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

Schedule: Weekly Sessions, 6 pm to 7:45 pm

October 1, 2020 Session I (Screening & Diagnosis)
October 8, 2020 Session II (Localized Disease)
October 15, 2020 Session III (Advanced Disease)
October 22, 2020 Session IV (Targeted Treatment)

THURSDAY, OCTOBER 1, 2020, 6 PM TO 7:45 PM

6:00 pm HOST AND EVENT CHAIR: Faina Shtern, MD, President and CEO, AdMeTech Foundation

6:10 pm SESSION I: SCREENING AND INITIAL EVALUATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER

Moderators:

Richard Babayan, MD, Professor and Emeritus Chairman, Department of Urology, Boston University School of Medicine and Boston Medical Center

E. David Crawford, M.D., Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer, Series Editor, Oncology Journal

Clare M.C. Tempany-Afdhal, MB BAO BCh, FACR, FISMRM, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women's Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization

6:15 pm	Yesterday, Today and Tomorrow of Screening: Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center; and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden
6:27 pm	Keynote Address - Liquid Diagnostics: E. David Crawford, MD
6:39 pm	Liquid Biopsy - Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation
6:51 pm	Q & A
6:53 pm	Current and Emerging Imaging Tools for Improving Risk Assessment and Selection of Patients for Biopsy: Clare Tempany, MD
7:05 pm	Commentary on High-Resolution, Real Time Ultrasound: Laurence Klotz, MD
7:17 pm	Q & A
7:19 pm	National Comprehensive Cancer Network (NCCN) Guidelines for Early Detection of Prostate Cancer 2020: Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel

Associate Professor, Department of Urology, University of Miami, Miller School of Medicine

Integrated Multi-Modality Diagnostic Evaluation: Sanoj Punnen, MD, Co-Chair of Genitourinary Site Disease Group,

7:43 pm – 7:45 pm Q & A

7:31 pm



VIRTUAL GLOBAL SUMMIT ON PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

THURSDAY, OCTOBER 8, 6 PM TO 7:45 PM

6:00 pm SESSION II. EVALUATION AND MANAGEMENT OF LOCALIZED AND RECURRENT PROSTATE CANCER

HOST: Adam Kibel, MD. Elliott Carr Cutler Professor of Surgery, Harvard Medical School; Chief of Urology,

Brigham and Women's Hospital and Dana-Farber Cancer Institute; and Member, Prostate Cancer Early Detection

Panel, National Comprehensive Cancer Network

Moderators:

Masoom Haider, MD, Professor of Radiology, University of Toronto and Senior Clinician Scientist, Lunenfeld Tanenbaum Research; Director of Machine Learning and Radiomics Lab; and Director of Sinai Health Systems Research MRI

Alan Pollack, MD, PhD, Professor and Chair, Radiation Oncology, University of Miami Miller School of Medicine; Interim Deputy Director, Sylvester Comprehensive Care Center; and Service Chief, Radiation Oncology, Jackson Memorial Hospital

Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF

6:08 pm	Genetic Cancer Profiling –		
	6:08 pm	Clinical Perspective: Allan Pollack, MD, PhD	
	6:20 pm	Germline Genome and Prostate Cancer Evolution and Aggressivity: Paul Boutros, MD, PhD, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA	
	6:32 pm	Q & A	
6:34 pm	In Vivo Imagin	g	
	6:34 pm	Current Clinical Utility of MRI and Multi-Modality Imaging: Masoom Haider, MD	
	6:46 pm	Non-Invasive Molecular Imaging and its Impact on Management of the Localized Disease and Suspected Recurrence: Andrei H. Iagaru, MD, FACNM, Professor of Radiology (Nuclear Medicine) and Chief, Division of Nuclear Medicine and Molecular Imaging; Director, Nuclear Medicine Residency Program; and Co-Director, PET-MRI Research Program, Stanford University	
	6:58 pm	Q & A	
7:00 pm	Biomarkers and Their Integration with Clinical Parameters, Imaging and Prognostic Instruments for Clinical Decisions: Matthew R. Cooperberg, MD, MPH		
7:12 pm	Q & A		
7:13 pm	Commentary on Assessing Outcomes for Advanced Imaging and Organ-Based Tracking Biopsy to Monitor Men on Active Surveillance - a Path Forward: Behfar Ehdaie, MD, MPH, Urologic Surgeon, Memorial Sloan Kettering Cancer Center		
7:22 pm	Current and Emerging Treatment Modalities - Role of Neoadjuvant Therapy: Adam Kibel, MD		
7:34 pm	Q & A		
7:36 pm – 7:45	pm Panel	and Q & A	



VIRTUAL GLOBAL SUMMIT ON PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

THURSDAY, OCTOBER 15, 2020, 6 PM TO 7:45 PM

6:00 pm SESSION III: ADVANCED PROSTATE CANCER

Host: Angelo DeMarzo, MD, PhD, Professor of Pathology and Associate Director of Cancer Research Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine

Moderators:

David Nanus, MD, Mark W. Pasmantier Professor and Chief, Hematology and Oncology, New York-Presbyterian, and Director of Genitourinary Oncology, Weill Cornell Medicine

Brandon Mahal, MD, Assistant Professor, Radiation Oncology, University of Miami Miller School of Medicine; and Assistant Director of Community Outreach and Engagement, Sylvester Comprehensive Cancer Center

6:08 pm	Overview of Diagnosis & Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease			
	6:08 pm	Precision Oncology of Advanced Prostate Cancer: Angelo DeMarzo, MD, PhD		
	6:20 pm	Systemic Disease and Circulating Tumor Cells: David Nanus, MD		
	6:32 pm	Q & A		
	6:34 pm	Precision Diagnosis - Defining Non-Metastatic and Oligometastatic Prostate Cancer vs. Systemic Disease: Jeremie Calais, MD, MSc, Assistant Professor, Clinical Research Program Director, Nuclear Medicine and Theranostics, University of California, Los Angeles		
	6:46 pm	Q & A		
6:47 pm	Molecular and Multi-Modality Imaging and Theranostics of Prostate Cancer			
	6:47 pm	Current State-of-the-Art: Wolfgang Weber, MD, Professor and Chair, Department of Nuclear Medicine, Klinikum der Isar, Technical University of Munich, Germany		
	6:59 pm	Future Directions: Philip Koo, MD, Division Chief, Diagnostic Imaging, Banner MD Anderson Cancer Center		
	7:11 pm	Q & A		

7:13 pm - 7:45 pm Panel and Q & A



VIRTUAL GLOBAL SUMMIT ON PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

THURSDAY, OCTOBER 22, 2020, 6 PM TO 7:45 PM

6:00 pm SESSION IV: IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT

Host: Peter Pinto, MD, Head of Prostate Cancer Section, Urologic Oncology Branch, Center for Cancer Research, National Cancer

Institute, National Institutes of Health

Moderators:

David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York

Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine

Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine

6:08 pm	Multimodality Diagnostics and Improved Target Definition, Patient Selection, Monitoring, Clinical Utility &
	Patient Outcomes

6:08 pm	Overview of Patient Selection and Outcomes from Urologic Perspective: Jim Hu, MD, MPH, Ronald Lynch Professor of Urologic Oncology and Professor of Urology, Weill Cornell Medicine; Director, Lefrak Center for Robotic Surgery; and Attending Urologist, New York-Presbyterian Hospital
6:20 pm	Q & A

6:22 pm Radiation Oncology Perspective on the Role of Multi-Modality and Molecular Imaging in Target Definition: Jason A. Efstathiou, MD, DPhil, Professor, Harvard Medical School; Director, Genitourinary Division, Department of Radiation Oncology; and Co-Director, Bertucci Center for GU Cancers, Massachusetts General Hospital

6:34 pm Current and Emerging Role of Radiogenomics in Risk Assessment: John Feller, MD, Founding Partner, Desert Medical Imaging and Chief Medical Officer, Halo Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine

Q & A 6:46 pm

6:50 pm Image-Guided Minimally-Invasive Whole Gland Treatment: Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of

Medicine, UCLA

7:02 pm High Intensity Focal Ultrasound and Other Focal Interventions - Emerging Data and Clinical Utility

vs. Standard Care (Active Surveillance and Whole-Gland Treatment with Surgery and Radiation): Andre Abreu, MD, Assistant Professor of Clinical Urology and Radiology and Director of Image-Guided Surgery and Focal Therapy of Prostate Cancer at University of South California,

Los Angeles

7:14 pm Q & A

7:20 pm - 7:45 pm Panel and Q & A

7:45 pm **ADJOURN**